← Oncology Approval Tracker

FDA DECISION ·

Lumakras

sotorasib · Amgen

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic non-small cell lung cancer with KRAS G12C detected by an FDA-approved test, after at least one prior systemic treatment.

LAMPGEN ANALYSIS

Why it matters

The original approval translates a specific KRAS substitution into a treatment selection criterion.

What research teams should watch

Confirm the G12C result and prior systemic line, and document liver safety follow-up and dose modifications.

PRIMARY RECORDS

Sources